AI systems in clinical practice

Decision support systems
TherapyEdge
TherapyEdge HIV™ is a Web-based decision support system for the treatment of HIV. It forms the first release module of TherapyEdge, a knowledge-based system for the treatment of chronic diseases.

developed by clinical domains keywords
TherapyEdge, Inc. USA HIV, chronic diseases, treatment Decision support systems, WWW
location commissioned status
TherapyEdge-HIV is in use in over 42 clinical sites (April 2005), 19 of which are in Africa, ranging from large hospitals to very rural clinics. Launched at ICAAC - 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, CHICAGO, December 17, 2001. In routine use. Marketed by Advanced Biological Laboratories (ABL) S.A., Luxembourg.
description
Therapy Edge logo TherapyEdge HIV™ graphically tracks and automatically processes a patient’s clinical data – including medical conditions, medications, genetic tests for drug resistance, drug efficacy and toxicity data – through an extensive knowledge base of pharmacological and clinical information created and maintained in collaboration with expert HIV clinicians and researchers. The system utilizes an AI engine and knowledge base to assess a patient’s current status and generate patient-specific, optimized treatment alternatives for a clinician to review and compare. In this way, the system can be used to generate comprehensive, individualized treatment plans for patients. TherapyEdge is available to subscribers via the Internet.

TherapyEdge’s real-time, intelligent alerting system automatically checks for drug interactions, medical conditions or side-effect issues, as well as abnormal lab results and drug dosing. Additionally, the system de-identifies patient data and provides a longitudinal database that can be queried for drug efficacy data, clinical outcomes and quality of care information. The system therefore supports the validation of effectiveness of health services and therapeutic interventions.

Version (3.2) of TherapyEdge-HIV was released by ABL, SA in early 2005. The new system incorporates a data warehouse for aggregation of data from on-site installations of TherapyEdge-HIV. There is a PDA data capture module, Rapid Capture Forms, for sites seeing large numbers of HIV patients; a patient interface, and advanced reporting tools (that include USAID and WHO Reports.)

The AI Therapy Evaluation Report has been updated to support treatment guidelines from numerous contries as well as localized drug formularies. ABL offers an HL7/XML module to communicate with other systems.

A demonstration of TherapyEdge HIV™ is available from Advanced Biological Laboratories (ABL) S.A. (registration required).

references

R. Boulme, D. Gonzalez and JC. Schmit. Storing genotypic resistance data and linking to other clinical information. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004.

[International AIDS Society]   [ABL S.A.]

" Background: Since mid-nineties, HIV sequencing has been extensively used to detect in research and in clinical routine HIV resistance associated mutations. Management of HIV nucleotide sequences is not easy as current database systems do not offer tools to handle genetic information. Methods: To develop: 1) a database enabling HIV sequences submission, analysis and storage; 2) automated tools for : a) interpretation of large number of sequences, b) real-time prevalence of main mutations; c) querying HIV sequences for specific patterns; and d) a standardized format for exchanging resistance information. Results: We designed an online relational database (HIV LogiCare, www.ablnetworks.org) which is implemented on Linux. ViroScorer technology enables to submit sequences, and uses the detected mutations to predict levels of resistance for each drug based on several algorithms. An in-house extensive ViroScorer release (LargeScale) allows to submit in one time larger datasets: outputs (mutations, interpretations) can be opened using Microsoft Excel. Each submitted sequence is stored in the database. Detected mutations are derived in five tables : one for protease, one for the reverse transcriptase, two for main resistance associated mutations (IAS-USA), and one for interpretations (each drug-algorithm combination: 112 interpretations). These tables can be queried for real-time surveillance of detected mutations (EpiVisor) or for a specific mutations pattern (HIVLib). A file in XML (extensible markup language) format is automatically generated to have the latest sample-related information (laboratory, resistance, quality control) ready for upload and exchange. Conclusions: A patient care monitoring system coupled with bioinformatics tools makes it easy to link resistance data to other parameters. Stored information (clinics, virology and resistance) can be exported in various formats and queried for surveillance program or research topics. "

contact links
United States:

TherapyEdge, Inc. PO Box 94
Topsfield, MA 01983, USA

(919) 386-8041 phone
(919) 287-2223 fax

Europe and Africa:

ABL SA
2 rue des Dalhias
L-1411, Luxembourg
Luxembourg

(+352) 2602-2225 phone
(+352) 2638-9776 fax

E: infoattherapyedge.com

 bullet  Advanced Biological Laboratories (ABL) S.A.  bullet  Demonstration of TherapyEdge HIV™ at ABL S.A. (registration required)  bullet  ABL [OC]
acknowledgements

Hank Head, ABL SA.

Entry on OpenClinical: February 8 2002
Last main updates: March 17 2002; November 01 2004; April 18 2005
Search this site
 

 

Privacy policy User agreement Copyright Feedback

Last modified:
© Copyright OpenClinical 2001-2007